These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 16581145)

  • 21. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.
    Dobrzycki S; Mezyński G; Kralisz P; Prokopczuk P; Nowak K; Kochman W; Zuk J; Bachórzewska-Gajewska H; Sawicki Z; Poniatowski B; Korecki J; Musiał WJ
    Kardiol Pol; 2006 Aug; 64(8):793-9; discussion 800-1. PubMed ID: 16981054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4.
    Peterson ED; Pollack CV; Roe MT; Parsons LS; Littrell KA; Canto JG; Barron HV;
    J Am Coll Cardiol; 2003 Jul; 42(1):45-53. PubMed ID: 12849658
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and cost-effectiveness of facilitated percutaneous coronary intervention compared with primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction transferred from community hospitals.
    Coleman CI; McKay RG; Boden WE; Mather JF; White CM
    Clin Ther; 2006 Jul; 28(7):1054-62. PubMed ID: 16990084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes.
    Westerhout CM; Hernández AV; Steyerberg EW; Bueno H; White H; Théroux P; Moliterno DJ; Armstrong PW; Califf RM; Wallentin LC; Simoons ML; Boersma E
    Eur Heart J; 2006 Dec; 27(24):2956-61. PubMed ID: 17093039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antithrombotic therapy for non-ST segment elevation myocardial infarction].
    Hölschermann H
    Hamostaseologie; 2006 May; 26(2):106-13. PubMed ID: 16676052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy and safety of combination glycoprotein IIbIIIa inhibitors and reduced-dose thrombolytic therapy-facilitated percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis of randomized clinical trials.
    Sinno MC; Khanal S; Al-Mallah MH; Arida M; Weaver WD
    Am Heart J; 2007 Apr; 153(4):579-86. PubMed ID: 17383297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antithrombotic therapy and the transition to the catheterization laboratory in UA/NSTEMI.
    Ferguson JJ; Wilson JM; Diez J
    Minerva Cardioangiol; 2007 Oct; 55(5):529-56. PubMed ID: 17912162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polish Registry of Acute Coronary Syndromes (PL-ACS). Characteristics, treatments and outcomes of patients with acute coronary syndromes in Poland.
    Poloński L; Gasior M; Gierlotka M; Kalarus Z; Cieśliński A; Dubiel JS; Gil RJ; Ruzyłło W; Trusz-Gluza M; Zembala M; Opolski G
    Kardiol Pol; 2007 Aug; 65(8):861-72; discussion 873-4. PubMed ID: 17853315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.
    Mehta RH; Greenbaum AB; Lokhnygina Y; Newby LK; Van De Werf F; Armstrong PW; Pieper KS; Califf RM; Granger CB; Harrington RA
    J Interv Cardiol; 2007 Oct; 20(5):299-306. PubMed ID: 17880325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proper use of glycoprotein IIb/IIIa inhibitors in patients with non-sT elevation acute coronary syndromes undergoing coronary angiography: frankly, my dear, I don't give a damn.
    Bovenzi F; De Luca L
    J Cardiovasc Med (Hagerstown); 2006 Mar; 7(3):166-8. PubMed ID: 16645380
    [No Abstract]   [Full Text] [Related]  

  • 32. [Acute coronary ischemic syndrome without ST elevation. Role of glycoprotein IIB/IIIA inhibitors and percutaneous coronary interventions].
    Peña Duque MA
    Arch Cardiol Mex; 2006; 76 Suppl 2():S249-51. PubMed ID: 17017111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical comparison of "normal-hours" vs "off-hours" percutaneous coronary interventions for ST-elevation myocardial infarction.
    Ortolani P; Marzocchi A; Marrozzini C; Palmerini T; Saia F; Aquilina M; Baldazzi F; Silenzi S; Taglieri N; Grosseto D; Bacchi-Reggiani ML; Guastaroba P; Grilli R; Branzi A
    Am Heart J; 2007 Aug; 154(2):366-72. PubMed ID: 17643590
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Transfer with GP IIb/IIIa inhibitor tirofiban for primary percutaneous coronary intervention vs. on-site thrombolysis in patients with ST-elevation myocardial infarction (STEMI): a randomized open-label study for patients admitted to community hospitals.
    Dobrzycki S; Kralisz P; Nowak K; Prokopczuk P; Kochman W; Korecki J; Poniatowski B; Zuk J; Sitniewska E; Bachorzewska-Gajewska H; Sienkiewicz J; Musial WJ
    Eur Heart J; 2007 Oct; 28(20):2438-48. PubMed ID: 17884846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of outcomes and safety of "facilitated" versus primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
    McKay RG; Dada MR; Mather JF; Mennet RR; Murphy DJ; Maloney KW; Hirst JA; Kiernan FJ
    Am J Cardiol; 2009 Feb; 103(3):316-21. PubMed ID: 19166682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet glycoprotein IIb/IIIa integrin inhibition in acute myocardial infarction.
    O'Shea C; Tcheng JE
    J Invasive Cardiol; 1999 Aug; 11(8):494-9. PubMed ID: 10745582
    [No Abstract]   [Full Text] [Related]  

  • 37. Glycoprotein IIb/IIIa receptor inhibitors in acute ST-elevation myocardial infarction: will the combination with thrombolytics become reality?
    Zeymer U
    J Thromb Thrombolysis; 2003 Apr; 15(2):91-7. PubMed ID: 14618075
    [No Abstract]   [Full Text] [Related]  

  • 38. Glycoprotein IIb/IIIa inhibitors improve mortality after aspiration thrombectomy in patients with ST-segment elevation myocardial infarction.
    Bajaj NS; Ather S; Gaba S; Aggarwal H; Arora P; Ghimire G; Bhatia V; Parashar A; Ahmed MI; Ahmed A; Leesar MA
    Int J Cardiol; 2015; 187():206-7. PubMed ID: 25839623
    [No Abstract]   [Full Text] [Related]  

  • 39. Early glycoprotein IIb/IIIa inhibitors in patients with non-ST-segment elevation myocardial infarction: are we ready to open the floodgates?
    Stone PH; Yeghiazarians Y
    J Am Coll Cardiol; 2003 Jul; 42(1):54-6. PubMed ID: 12849659
    [No Abstract]   [Full Text] [Related]  

  • 40. Glycoprotein IIb/IIIa inhibition and long-term benefit: the stuff of dreams?
    Montalescot G
    Eur Heart J; 2004 Sep; 25(18):1562-4. PubMed ID: 15351154
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.